Stock KIN KINDRED BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Kindred Biosciences, Inc. Stock

Equities

KIN

US4945771099

Biotechnology & Medical Research

Chart Kindred Biosciences, Inc.

Dynamic Chart

Latest news about Kindred Biosciences, Inc.

ObsEva Names Chief Strategy Officer MT
Vaxart, Inc. acquired KindredBio's manufacturing equipment and GMP manufacturing facility in California from Kindred Biosciences, Inc. CI
Kindred Biosciences, Inc. Announces Board Changes CI
Elanco Animal Health Incorporated : Closes Purchase of Kindred Biosciences for About $444 Million MT
Kindred Biosciences, Inc.(NasdaqCM:KIN) dropped from S&P Global BMI Index CI
Kindred Biosciences, Inc.(NasdaqCM:KIN) dropped from S&P TMI Index CI
Kindred Biosciences, Inc.(NasdaqGM:KIN) dropped from NASDAQ Composite Index CI
Elanco Animal Health Incorporated completed the acquisition of Kindred Biosciences, Inc.. CI
Today on Wall Street: Markets ride momentum ahead of Jackson Hole Our Logo
ANALYST RECOMMENDATIONS : Adobe, Baozun, Fafetch, Hydro One, Ontrak Our Logo
KINDRED BIOSCIENCES : Stifel Nicolaus Downgrades Kindred Biosciences to Hold From Buy, Keeps $9 Price Target MT
Kindred Biosciences, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Insider Trends: Kindred Biosciences Insider Continues 90-Day Selling Trend MT
Kindred Biosciences, Inc.(NasdaqCM:KIN) dropped from Russell 3000E Index CI
Kindred Biosciences, Inc.(NasdaqCM:KIN) dropped from Russell 2500 Growth Index CI
More news

Analyst Recommendations on Kindred Biosciences, Inc.

ANALYST RECOMMENDATIONS : Adobe, Baozun, Fafetch, Hydro One, Ontrak Our Logo
KINDRED BIOSCIENCES : Stifel Nicolaus Downgrades Kindred Biosciences to Hold From Buy, Keeps $9 Price Target MT
KINDRED BIOSCIENCES : Lake Street Downgrades Kindred Biosciences to Hold from Buy, Adjusts Price Target to $9.25 from $12 MT
KINDRED BIOSCIENCES : HC Wainwright Downgrades Kindred Biosciences to Neutral From Buy, Adjusts Price Target to $9.25 From $9 MT
DJ Industrial : US Stocks Drop After Some FOMC Members Signal Earlier Rate Hikes MT
More recommendations

Press releases Kindred Biosciences, Inc.

Kindred Biosciences : Market Offering Agreement (Form 8-K) PU
KINDRED BIOSCIENCES, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year (form 8-K) AQ
KINDRED BIOSCIENCES, INC. : Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K) AQ
Kindred Bio: Q2 Earnings Snapshot AQ
KINDRED BIOSCIENCES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) AQ
More press releases

News in other languages on Kindred Biosciences, Inc.

Obseva nomme une responsable de la stratégie
Obseva ernennt Katja Buhrer zum Chief Strategy Officer
MÄRKTE USA/Wall Street mit Fed-Signal für frühere Zinswende schwächer
MÄRKTE USA/Wall Street tritt vor Fed-Entscheid auf der Stelle
MÄRKTE USA/Anleger halten sich vor Fed-Entscheid zurück
More news

Managers and Directors - Kindred Biosciences, Inc.

Managers TitleAgeSince
Jay Peterson PRN
 Corporate Officer/Principal - -
Members of the board TitleAgeSince
David Pugh BRD
 Director/Board Member - 21-08-26
Kathleen St. Louis BRD
 Director/Board Member - 02-08-26
Jinee Majors BRD
 Director/Board Member - 21-08-26
More insiders

Company Profile

Kindred Biosciences, Inc. is a United States-based company. The Company is a veterinary biopharmaceutical company developing medicines for cats, dogs and horses. Its product is Zimeta (dipyrone injection). The Company is engaged in revolutionizing veterinary therapeutic biologics, such as monoclonal antibodies and recombinant proteins.
Sector
Biotechnology & Medical Research
More about the company

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.82% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.89% 96.07B
ARGENX SE Stock argenx SE
-1.63% 21.66B
BIONTECH SE Stock BioNTech SE
-17.59% 20.77B
GENMAB A/S Stock Genmab A/S
-6.87% 18.53B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-40.31% 16.91B
BEIGENE, LTD. Stock BeiGene, Ltd.
-27.65% 13.79B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+0.33% 13.33B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+21.08% 10.94B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. KIN Stock